Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

(2023) Maria Carmela Piccirillo et al.   Journal of Thoracic Oncology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

(2022) S. Peters et al.   ANNALS OF ONCOLOGY

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

(2022) Javier Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

(2021) Paul Baas et al.   LANCET

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity

(2021) Luka Brcic et al.   Cancers

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

(2021) Nicoletta Colombo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

(2021) Dean A Fennell et al.   LANCET ONCOLOGY

Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma

(2020) Natasha K. Brockwell et al.   Translational Lung Cancer Research

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

(2019) Arnaud Scherpereel et al.   LANCET ONCOLOGY

Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort

(2019) Solenn Brosseau et al.   Clinical Lung Cancer

Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

(2018) Samuel G. Armato et al.   Journal of Thoracic Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Alternative metrics for assessing clinical benefit with immunotherapy in oncology

(2017) E. Chan et al.   OncoImmunology

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

The Worldwide Pandemic of Asbestos-Related Diseases

(2013) Leslie Stayner et al.   Annual Review of Public Health

Multiple Testing in Group Sequential Trials Using Graphical Approaches

(2013) Willi Maurer et al.   Statistics in Biopharmaceutical Research

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER